Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Baxter
Merck
Fuji
Daiichi Sankyo

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 5,416,007

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,416,007
Title: Enhanced proteolytic cleavage of recombinant fusion proteins
Abstract:Disclosed are methods for increasing the yield of intact target proteins by cleaving fused polypeptides made by recombinant DNA techniques. The fused polypeptides are designed at the DNA level to have a preselected primary cleavage site in a pendant polypeptide fused to a protein of interest. Structural features of the fused polypeptide and cleavage reaction environment are controlled to favor cleavage by a preselected cleavage agent at the primary cleavage site over a second cleavage agent-sensitive amino acid sequence in the target protein. The cleavage reaction is terminated before completion when the ratio of intact target protein to truncated, cleaved target protein is optimized, and the remaining reaction mixture comprising uncleaved fused polypeptide is resubjected to the cleavage agent. The presence of charged organic molecules in the cleavage reaction mixture favors cleavage at the primary cleavage site. The endopeptidase used for cleavage may be immobilized on an insoluble support matrix.
Inventor(s): Charette; Marc F. (West Roxbury, MA), Crea; Roberto (Boston, MA), Cohen; Charles M. (Medway, MA)
Assignee: Creative BioMolecules, Inc. (Hopkinton, MA)
Application Number:08/273,870
Patent Claims:see list of patent claims

Details for Patent 5,416,007

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Try a Free Trial Creative BioMolecules, Inc. (Hopkinton, MA) 2012-05-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
Cipla
Federal Trade Commission
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.